Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: A double-blind randomised placebo controlled 6-month trial

BMC Family Practice

Volumn 8, Issue , 2007, Pages

  Paile Hyvärinen, Maria ^a   Wahlbeck, Kristian ^a,b   Eriksson, Johan G ^a,c  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b VAASA CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO; ANTIDEPRESSANT AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT CARE; PRIMARY MEDICAL CARE; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WELLBEING; BLOOD; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; MENTAL HEALTH; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD GLUCOSE; DEPRESSION; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS INDICATORS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; PAROXETINE; QUALITY OF LIFE;

EID: 34447337219     PISSN: None     EISSN: 14712296     Source Type: Journal    
DOI: 10.1186/1471-2296-8-34     Document Type: Article

References (18)

1. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. MI Harris KM Flegal CC Cowie MS Eberhardt DE Goldstein RR Little HM Wiedmeyer DD Byrd-Holt, Diabetes Care 1998 21 4 518 524 10.2337/diacare.21.4.518 9571335
2. Incidence, prevalence and risk factors for non-insulin-dependent diabetes mellitus. RG Nelson JE Everhart WC Knowler PH Bennett, Prim Care 1988 15 2 227 250 3290917
3. Effect of weight loss on glucose disposal in obese and obese diabetic patients. A Golay JP Felber M Dusmet F Gomez B Curchod E Jequier, Int J Obes 1985 9 3 181 191 3902687
4. Prevalence of depression in adults with diabetes. An epidemiological evaluation. JA Gavard PJ Lustman RE Clouse, Diabetes Care 1993 16 8 1167 1178 10.2337/diacare.16.8.1167 8375247
5. Fluoxetine in the treatment of obese type 2 diabetic patients. M O'Kane PG Wiles JK Wales, Diabet Med 1994 11 1 105 110 8181239
6. A randomized double-blind clinical trial of fluoxetine in obese diabetics. DS Gray K Fujioka W Devine GA Bray, Int J Obes Relat Metab Disord 1992 16 Suppl 4 S67 72 1338389
7. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub). LR Levine GG Enas WL Thompson RL Byyny AD Dauer RW Kirby TG Kreindler B Levy CP Lucas HH McIlwain, Int J Obes 1989 13 5 635 645 2583918
8. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. P Maheux F Ducros J Bourque J Garon JL Chiasson, Int J Obes Relat Metab Disord 1997 21 2 97 102 10.1038/sj.ijo.0800372 9043962
9. Sertraline in coexisting major depression and diabetes mellitus. PJ Goodnick A Kumar JH Henry VM Buki RB Goldberg, Psychopharmacol Bull 1997 33 2 261 264 9230640
10. Trends in Prescribing of Selective Serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. PA Pirraglia RS Stafford DE Singer, Prim Care Companion J Clin Psychiatry 2003 5 4 153 157 15213776
11. Subthreshold psychiatric disorders in primary care: prevalence and associated characteristics. P Rucci S Gherardi M Tansella M Piccinelli D Berardi G Bisoffi MA Corsino S Pini, J Affect Disord 2003 76 1-3 171 181 10.1016/S0165-0327(02)00087-3 12943947
12. Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial. M Paile-Hyvarinen K Wahlbeck J Eriksson, BMC Family Practice 2003 4 1 7 12747810 10.1186/1471-2296-4-7
13. Diagnostic and statistical manual of mental disorders. Fourth Edition, Text Revision edn. Washington, DC, American Psychiatric Association 2000
14. The hospital anxiety and depression scale. AS Zigmond RP Snaith, Acta Psychiatr Scand 1983 67 6 361 370 6880820
15. The RAND 36-Item Health Survey 1.0. RD Hays CD Sherbourne RM Mazel, Health Econ 1993 2 3 217 227 10.1002/hec.4730020305 8275167
16. Acute angle closure glaucoma associated with paroxetine. T Eke AK Bates, BMJ 1997 314 7091 1387 9161312
17. Antidepressant interactions with warfarin. D Duncan K Sayal H McConnell D Taylor, Int Clin Psychopharmacol 1998 13 2 87 94 10.1097/00004850-199803000- 00006 9669190
18. Fluoxetine treatment of the obese diabetic. DS Gray K Fujioka W Devine GA Bray, Int J Obes Relat Metab Disord 1992 16 3 193 198 1317828